These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32154575)

  • 21. Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.
    Ozer O; Yorulmaz G
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):110-111. PubMed ID: 33115581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 Inhibitors May Predispose to Ketoacidosis.
    Taylor SI; Blau JE; Rother KI
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ketogenic diet as a trigger for diabetic euglycaemic ketoacidosis in a patient under treatment with iSGLT2].
    Nubiola A; Ternianov A; Remolins I
    Hipertens Riesgo Vasc; 2020; 37(1):39-41. PubMed ID: 31734176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus.
    Wohlrab P; Kainz M; Schiferer A; Zapletal B; Tschernko E
    J Cardiothorac Vasc Anesth; 2022 Jul; 36(7):2066-2069. PubMed ID: 34465512
    [No Abstract]   [Full Text] [Related]  

  • 26. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
    Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
    Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
    Ahmed M; McKenna MJ; Crowley RK
    Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
    Leader R; Cowen J; Rajeev SP
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The cardiovascular outcome is critical].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(3):68. PubMed ID: 27119710
    [No Abstract]   [Full Text] [Related]  

  • 31. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
    Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T
    J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death.
    Everett BM; Hiatt WR
    Circulation; 2016 Sep; 134(10):773-5. PubMed ID: 27601559
    [No Abstract]   [Full Text] [Related]  

  • 34. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
    Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
    Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
    Bilgin S; Duman TT; Kurtkulagi O; Yilmaz F; Aktas G
    J Coll Physicians Surg Pak; 2022 Jul; 32(7):928-930. PubMed ID: 35795946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
    Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
    Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
    Chou YM; Seak CJ; Goh ZNL; Seak JC; Seak CK; Lin CC
    Medicine (Baltimore); 2018 Jun; 97(25):e11056. PubMed ID: 29923997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
    Cherney DZ; Udell JA
    Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
    Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.